Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of some unusual options trading activity on Monday. Stock traders bought 13,040 call options on the company. This represents an increase of 42% compared to the average volume of 9,161 call options.

Recursion Pharmaceuticals Stock Up 15.9 %

Shares of RXRX stock opened at $6.99 on Tuesday. The firm’s fifty day moving average price is $6.76 and its two-hundred day moving average price is $7.18. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 1 year low of $5.60 and a 1 year high of $15.74. The firm has a market capitalization of $2.00 billion, a P/E ratio of -4.57 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) EPS. On average, equities analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares in the company, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 107,788 shares of company stock worth $724,691 over the last ninety days. Corporate insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth $25,000. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the period. KBC Group NV lifted its stake in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the last quarter. Amalgamated Bank grew its holdings in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the third quarter worth approximately $69,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

RXRX has been the topic of several recent analyst reports. Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.